BioMarin’s statement on COVID-19 situation

BioMarin is a world leader in developing and commercializing innovative therapies for rare genetic diseases. We have developed a variety of business continuity plans as part of ongoing operations and are implementing those plans during the coronavirus pandemic. We are regularly reviewing our operations to ensure the safety of our employees and continued access to our therapies for our patients. We are taking all possible measures to limit the potential impact on our supply chain.

Due to the unprecedented demand placed on healthcare services as a result of the coronavirus pandemic, we are aware that ERT treatment for patients may have been interrupted because hospital resources have been reallocated to support emergency care for people with COVID-19. BioMarin recognises the concerns of patients and their carers, and is working with governments, health authorities and sick funds, as well as patient organisations, where possible to explore options and solutions to support continued access to treatment.

We are also aware that some patients have expressed concerns about attending their weekly infusions in hospitals and may be unsure about what they should do. Whilst BioMarin cannot comment on specific hospital advice for patients or provide specific guidance about attending these ERT outpatient clinics/centre we do recommend patients contact their ERT clinic or centres for relevant guidance.

BioMarin’s patient information leaflet regarding ERT therapy contains specific information on the administration and use of the product. Please contact your nurse/physician for more specific and individual medical advice on managing your ERT therapy during this pandemic period.

BioMarin is committed to the MPS community across our region and we are striving to help maintain ongoing therapy for patients during this challenging time.